You are here

  • Home
  • Archive
  • Volume 9, Issue 11
  • Correction: KEYNOTE-022 part 3: a randomized, double-blind, phase 2 study of pembrolizumab, dabrafenib, and trametinib in BRAF-mutant melanoma

Article Text

Article menu

See original article:

Download PDFPDF

Correction
Correction: KEYNOTE-022 part 3: a randomized, double-blind, phase 2 study of pembrolizumab, dabrafenib, and trametinib in BRAF-mutant melanoma

http://dx.doi.org/10.1136/jitc-2020-001806corr1

Statistics from Altmetric.com

    Ferrucci PF, Di Giacomo AM, Del Vecchio M for the KEYNOTE-022 international team, et al. KEYNOTE-022 part 3: a randomized, double-blind, phase 2 study of pembrolizumab, dabrafenib, and trametinib in BRAF-mutant melanoma. J ImmunoTher Cancer 2020;8:e001806. doi: 10.1136/jitc-2020-001806

    This article has been corrected since it was first published. Dr. Queirolo’s affiliations have been updated to the following: ‘IEO European Institute of Oncology IRCCS, Milan, Italy’ and ‘Ospedale Policlinico San Martino IRCCS, Genoa, Italy’.

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Copyright information:

    © Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.